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Background: Although cystitis glandularis (CG) is a common benign urinary bladder epithelial abnormality, it
remains unclear whether CG is a premalignant lesion. Cyclooxygenase-2 (COX-2) and B-cell lymphoma-2 (Bcl-2)
overexpression has recently been reported as a potential tumor initiator or promoter. We evaluated and compared
COX-2 and Bcl-2 expression in CG, chronic cystitis (CC), and primary vesicle adenocarcinoma (ADC) tissues.
Methods: We conducted a retrospective study to investigate COX-2 and Bcl-2 levels in CG and ADC. We obtained
tissue samples from 75 patients (including 11 cases of CC, 30 typical cases of CG (CGTP), 30 cases of intestinal CG (CGIT),
and 4 cases of ADC) between 1989 and 2009 from the Surgical Pathology Archives of the No. 2 People’s Hospital of
Zhenjiang, affiliated with Jiangsu University. COX-2 and Bcl-2 immunohistochemical staining was performed on all
tissues. Nine normal bladder epithelial specimens were evaluated as control samples. Correlations between COX-2 and
Bcl-2 expression in CG were also analyzed.
Results: COX-2 and Bcl-2 expression was higher in the ADC group compared to other groups (p < 0.05). COX-2 and
Bcl-2 levels were higher in the CGIT group compared to the CGTP group (p = 0.000 for both). The CGIT and CGTP groups
both showed higher COX-2 expression compared to the CC group (p = 0.000 for both). There was no difference in Bcl-2
expression between the CGTP and CC groups (p = 0.452). Additionally, the difference in COX-2 and Bcl-2 expression
between the control and CC groups was also insignificant (p = 0.668 and p = 0.097, respectively). Finally, we found that
COX-2 and Bcl-2 levels were positively related (r = 0.648, p = 0.000).
Conclusion: COX-2 and Bcl-2 overexpression in the CG group suggests that CG, particularly the intestinal type, may be a
premalignant lesion that converts into a tumor in the presence of carcinogens.
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Cystitis glandularis (CG) is a common benign epithelial
abnormality that occurs in the presence of chronic in-
flammation [1,2]. Based on morphology and behavior,
CG has been subdivided into two subtypes. Typical CG
(CGTP) is characterized by nests of columnar epithelial
cells within the bladder lamina propria that form glan-
dular structures. The intestinal type (CGIT) has similar* Correspondence: doctorjxb73@njmu.edu.cn
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reproduction in any medium, provided the orglandular architecture in the lamina propria but contains
abundant mucin-secreting goblet cells in the lining
epithelium [3]. Although the cause of CG is debatable
[4], it is generally agreed that in the presence of chronic
inflammation, the bladder mucosa becomes hyperproli-
ferative. When proliferation projects into the lamina
propria, epithelial nests (von Brunn’s nests) [5] and cyst-
itis cystica or glandular lesions (CG) form [5,6]. CG,
particularly the intestinal type, has been described as
premalignant; however, not all studies agree with this
conclusion [3,7]. Due to rare reported instances of CG
progression to adenocarcinoma or CG associated withhis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sequent bladder adenocarcinoma remains unclear.
Cyclooxygenase is an important enzyme that catalyzes
the conversion of arachidonic acid to prostaglandin.
COX-1 is constitutively expressed in most tissues and
regulates multiple physiological processes. In contrast,
COX-2 is frequently undetectable in normal tissues, but
can be induced by a variety of stimuli, including mito-
gens, cytokines, growth factors, and hormones, thereby
resulting in inflammation and cellular proliferation [8].
COX-2 overexpression is observed in chronic inflamma-
tion as well as in various tumors, including bladder,
prostate, colon, and lung [9-12]. To this end, we assessed
the differential expression of COX-2 in normal bladder
transitional cell tissue, chronic cystitis, two subtypes of
CG, and bladder adenocarcinoma tissue. In addition, we
determined if COX-2 expression is associated with ex-
pression of Bcl-2, a regulator and marker of apoptosis.
Methods
Patient samples
Tissues from 75 patients, including 60 cases of CG, 11
cases of chronic cystitis (CC), and 4 cases of primary
vesicle adenocarcinoma (ADC), were obtained from the
Surgical Pathology Archives of the No. 2 People’s Hos-
pital of Zhenjiang, affiliated with Jiangsu University be-
tween 1989 and 2009. Normal bladder specimens from
nine subjects who underwent cystectomy for benign
causes were used as controls. The Institutional Review
Board of Nanjing Medical University (Nanjing, China)
approved this study. At the time of patient recruitment,
written informed consent was obtained from all partici-
pants. We classified CG into CGTP and CGIT based on
routine hematoxylin and eosin-stained sections. One of
the ADC patients had the intestinal type of CG and
interrupted use of antibiotics rather than intravesical
instillation of the anticancer agent. Another patient had
neurogenic bladder with suprapubic cystostomy for fif-
teen years. The other two patients had classic bladder
exstrophy with an unsuccessful initial closure.
Immunohistochemistry and staining evaluation
Sections (5 μm thick) were cut from formalin-fixed,
paraffin-embedded tissue blocks and stained with hema-
toxylin and eosin. Additional sections from appropriately
selected blocks were cut for use in immunohistoche-
mical analyses as described previously [13,14]. Two
primary antibodies were used for immunochemical stain-
ing: monoclonal antibodies against COX-2 (monoclonal
mouse anti-human D12; Santa Cruz Biotechnology, USA)
and Bcl-2 (monoclonal mouse anti-human; Dako, Carpin-
teria, USA). Briefly, sections were baked for 2 hour at 72°C
and deparaffinized by sequential immersion in xylene, 95%
ethanol, 80% ethanol, and distilled water for 5 min each.Next, slides were placed in an autoclave containing anti-
gen retrieval solution (0.1 M citrate buffer from BDH at
pH 6.0) for 2 min at 121°C. Diluted primary antibodies
(100 μl) were applied to the sections and slides were incu-
bated in a humid chamber for 2 h at 37°C. Slides were
rinsed gently with PBS and placed in a fresh PBS bath for
5 min. Next, one or two drops of diluted biotinylated sec-
ondary goat anti-mouse antibodies (Dako Cytomation)
were applied to the sections and the slides were incubated
in a humid chamber for 2 h at 37°C. After rinsing, one or
two drops of streptavidin-horseradish peroxidase reagent
(Dako Cytomation) was added to the sections and slides
were incubated for 30 min at 37°C. Next, the prepared
DAB substrate chromogen solution was applied to the sec-
tions and slides were incubated in the dark at room
temperature for 5 min. Mayer's hematoxylin stain was used
as a counterstain, and slides were dehydrated and mounted.
Staining was evaluated as described previously [14,15].
Briefly, two pathologists who were unaware of the clinical
data scored immunohistochemical expression in a semi-
quantitative fashion. Expression levels were assessed by
evaluating the percentage of the cell that was stained, and
recorded as absent, weakly, moderately, or markedly posi-
tive. (5-25% indicated weakly, 25-50% indicated moder-
ately, >50% indicated markedly) Using light microscopy,
the mean percentage of \ positively stained cells in each
section was calculated from three dense, medium, and
light staining areas. In each area, the percentage of brown
stained cells was calculated from the total number of
countable cells in five high power fields. Therefore, ex-
pression scoring was determined to be discernible and
reproducible.
Statistical analyses
Kruskal-Wallis H tests were employed to evaluate differ-
ences in the amount of COX-2 and Bcl-2 expression among
control, CC, CGTP, CGIT and ADC specimens. To further
compare the expression of two groups, we performed
Mann–Whitney U tests. Spearman’s tests were used to
analyze the correlation between COX-2 and Bcl-2 expres-
sion in CG specimens. P values less than 0.05 were consid-
ered significant, and all P values are two-sided. All analyses
were performed using SPSS version 13.0 (SPSS, USA).
Results
The immunohistochemical staining results are summa-
rized in Table 1, and typical examples from the CGIT and
ADC groups are shown in Figure 1. There were significant
differences in COX-2 and Bcl-2 expression among the five
groups (χ2 = 58.917, p = 0.000; χ2 = 50.993, p = 0.000, re-
spectively). The ADC group showed the highest levels of
COX-2 and Bcl-2 expression compared to the other
groups (p < 0.05). COX-2 and Bcl-2 expression levels were
higher in the CGIT group compared to the CGTP group




Control CC CGTP CGIT ADC Control CC CGTP CGIT ADC
Absent 8 (88.9%) 9 (81.8%) 1 (3.3%) 0 (0%) 0 (0%) 8 (88.9%) 6 (54.5%) 11 (36.7%) 0 (0%) 0 (0%)
Weak 1 (11.1%) 2 (18.2%) 18 (60.0%) 3 (10.0%) 0 (0%) 1 (11.1%) 4 (36.4%) 18 (60.0%) 9 (30.0%) 0 (0%)
Moderate 0 (0%) 0 (0%) 11 (36.7%) 22 (73.3%) 1 (25.0%) 0 (0%) 1 (9.1%) 1 (3.3%) 20 (66.7%) 2 (50.0%)
Marked 0 (0%) 0 (0%) 0 (0%) 5 (16.7%) 3 (75.0%) 0 (0%) 0 (0%) 0 (0%) 1 (3.3%) 2 (50.0%)
CC: Chronic cystitis; CGTP: Typical type of cystitis glandularis; CGIT: Intestinal type of cystitis glandularis; ADC: Adenocarcinoma of bladder.
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and both of these groups showed higher COX-2 expres-
sion compared to the CC group (Z = −5.227, p = 0.000;
Z = −4.482, p = 0.000, respectively). However, the differ-
ence in Bcl-2 expression between the CGTP and CC
groups was not significant (Z = −0.752, p = 0.452). COX-2
and Bcl-2 levels were not different between the control and
CC groups (Z = −0.429, p = 0.668; Z = −1.658, p = 0.097,
respectively).
To determine whether increased COX-2 expression
was associated with up-regulation of the anti-apoptotic
protein Bcl-2 in CG patients, Spearman’s tests were per-
formed to analyze the correlation between expression of
the two proteins in specimens. We found that COX-2
and Bcl-2 expression were positively related (r = 0.648,
p = 0.000).
Discussion
COX-2 overexpression contributes to tumorigenesis
through multiple and complex mechanisms [9]. Liu et al.Figure 1 Immunohistochemical staining to evaluate Cox-2 and Bcl-2 l
CGIT. B. Bcl-2 expression in CGIT. C. COX-2 expression in ADC. D. Bcl-2 expreported that strong COX-2 expression in murine mam-
mary gland epithelial cells resulted in breast tumor de-
velopment [16]. Nevertheless, other mouse models of
skin carcinogenesis found that COX-2 plays a role in
tumor promotion rather than initiation [17,18]. In the
current study, we observed that COX-2 expression in
CGIT and CGTP specimens were significantly higher
compared to CC and control. CGIT tissue had a stron-
ger COX-2 expression compared to CGTP. Additionally,
COX-2 was aberrantly expressed in ADC tissue. These
data suggest that the COX-2 overexpression in these
two CG subtypes likely contribute to sensitizing prema-
lignant lesions to genotoxic carcinogens.
Apoptosis is a programmed cell death process that de-
pends on a balance of pro- and anti-apoptotic factors. It is
vital for tissue homeostasis and defense against pathogens.
Decreased apoptosis has been observed in premalignant
lesions. It is well known that COX-2 overexpression in-
creases expression of the proto-oncogene Bcl-2 and in-
hibits apoptosis [19]. Bcl-2, the first apoptotic regulatorocalization (original magnification 400×). A. Cox-2 expression in
ression in ADC.
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oncogene in follicular lymphomas [20]. Unlike other
oncogenes that increased cell proliferation, Bcl-2 inhib-
ited programmed cell death and affected the apoptotic
pathway, which are critical for cancer development
[19]. Our results demonstrate that Bcl-2 expression in
CGIT, but not in CGTP, was significantly higher com-
pared to CC and control. However, ADC cases had the
highest levels of Bcl-2. Additionally,, Bcl-2 expression
in CG cases was positively related to COX-2 expres-
sion, similar to the report by Tsujii et al. [21]. These
data suggest that impaired apoptosis may occur both in
both CG subtypes and play a critical role in premalig-
nant lesions.
Several reports have shown that adenocarcinoma of
the bladder is associated with CG [22-25]. However,
after more than ten years of data tracking, Corica et al.
reported that none of the 53 patients with CG devel-
oped bladder cancer [26]. As a result, the association
between CG and adenocarcinoma remains unclear. Al-
though inflammation is regarded as a possible initiator
of cancer [27,28] and COX-2 and Bcl-2 expression were
reported to be tumor initiators or promoters [28], the
malignant potential of CG should be examined in future
studies.
In conclusion, COX-2 and Bcl-2 overexpression in CG
suggests that CG, particularly the intestinal type, may be
a premalignant lesion that converts into a tumor in the
presence of carcinogens. However, further molecular
and clinical studies are needed to test this hypothesis.
Conclusion
COX-2 and Bcl-2 overexpression in CG suggests that
CG, particularly the intestinal type, may be a premalig-
nant lesion that converts into a tumor in the presence of
carcinogens.
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